Dear Sir, Please find newspaper Advertisement of Unaudited Financial Statement for the Quarter & half yearly ended on 30.09.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem has published its unaudited standalone financial results for the quarter ended 30 September 2025 and the half year (H1 FY26) ended the same date. Total income from operations for Q2 FY26 stood at Rs. 2,606.86 lakhs, while net profit after tax came in at Rs. 476.17 lakhs for the quarter and Rs. 931.06 lakhs for H1 FY26. Basic and diluted EPS for Q2 FY26 was Rs. 0.050, down from Rs. 0.088 in the same quarter last year. The board approved the results on 14 November 2025 and the statutory auditors issued a limited review report. The detailed results are available on the BSE website and the company's website.
Standalone profitability is weaker year-on-year, with Q2 EPS dropping roughly 43% from Rs. 0.088 to Rs. 0.050 despite steady revenue levels, signalling possible margin pressure. Investors should watch the next few quarters for confirmation of a trend before drawing strong conclusions.